Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis’ Cell-based Vaccine: Seasonal Approval With Pandemic Implications

This article was originally published in The Pink Sheet Daily

Executive Summary

The Flucelvax flu vaccine is the first approved in the U.S. that is derived from cell-based technology instead of the traditional egg-based process. It will be made at Novartis’ Holly Springs, N.C. plant.

Advertisement

Related Content

Flu Vaccines Likely To Remain Immune From Comparative Effectiveness
Drug Shortages: FDA Wants Ideas To Boost Manufacturing Quality For Strategic Plan
Protein Sciences To Begin Selling Novel Flu Vaccine; Flublok Has Virus-Free Appeal
Pressure For Bexsero: Fate Of Novartis Vaccines Unit Hangs On Success
Flu Vaccine Production Down Slightly This Season; Strains Get Overhaul
Bioterror “Strategic Investor” Initiative Must Be Resolved As House, Senate Pass Dueling Bills
Chick Eggs Cannot Yield Enough Vaccine For Pandemic: NYAS Swine Flu Mtg.

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073538

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel